– In the phase 3 PRIMIS trial, cilofexor 100 mg daily did not significantly reduce the proportion of patients with histological fibrosis progression (Ludwig stage increase ≥1) at 96 weeks compared with placebo in non‑cirrhotic large‑duct primary sclerosing cholangitis (PSC).
– Fibrosis progression occurred in 31% of cilofexor‑treated patients versus 33% with placebo (treatment difference −1.4%; 95% CI −15.2 to 12.3; p=0.42); the study was stopped early for futility.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
